Nordhealth AS (NORDH) Fair Value & Analysis
Healthcare · NO · Market cap 2.2B NOK
Fair value as of: Jun 24, 2026
Analysis
Nordhealth AS (NORDH) currently trades at kr 24.60, while our model-based Fair Value estimate is kr 6.26 — implying the stock looks roughly 74.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Nordhealth AS provides healthcare software solutions in Norway, Finland, Sweden, the United Kingdom, Denmark, DACH, and internationally. Its products include Provet, a practice management software platform for veterinary clinics and enterprise groups, providing appointment scheduling, patient management, electronic health records, billing and invoicing, reporting and analytics, government compliance tools, communication features, inventory management, and workflow automation; Diarium, a PMS for therapists that streamlines therapy sessions, booking, and invoicing; Physica, a PMS for physiotherapists; Psykbase, a PMS for psychologists and psychiatrists; EasyPractice, a PMS for therapists; and various PMS for veterinarians under the Vetserve, Sanimalis, Vetvision, and Vetera names. The company's products comprise Nordhealth Connect, a communication platform for patients and healthcare professionals; and Navisec, a digital learning environment for training and orientation. In addition, …
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Nordhealth AS (NORDH) undervalued?
What is the fair value of NORDH?
What is the quality score of NORDH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.